Indication
For the treatment of cystic fibrosis (CF) in patients aged 2 years and older who are homozygous for the F508del mutation in the CFTR gene.

Medicine details

Medicine name:
lumacaftor-ivacaftor (Orkambi)
SMC ID:
SMC2182
Pharmaceutical company
Vertex Pharmaceuticals Ltd
BNF chapter
Submission type
Full
Status
Publication due date:
12 August 2019
SMC meeting date:
02 July 2019
Patient group submission deadline:
06 May 2019